Literature DB >> 1108735

Therapeutic use of inducers of interferon on Herpes simplex keratitis in humans.

M A Galin, E Chowchuvech, B Kronenberg.   

Abstract

The double-stranded RNA interferon inducer polyinosinic-polycytidylic acid (In-Cn) was used to treat acute dendritic keratitis in man in a double-blind manner with IDU. The success rate for this agent was similar to IDU and was found efficacious in cases not responsive to IDU. Prophylaxis with In-Cn did not prevent recurrences of epithelial herpes, but such recurrences were responsive to IDU or In-Cn.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1108735

Source DB:  PubMed          Journal:  Ann Ophthalmol        ISSN: 0003-4886


  7 in total

Review 1.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

Review 2.  Antiviral agents: action and clinical use.

Authors:  T W Chang; D R Snydman
Journal:  Drugs       Date:  1979-11       Impact factor: 9.546

Review 3.  Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.

Authors:  R B Pollard
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

4.  The treatment of herpes simplex virus epithelial keratitis.

Authors:  K R Wilhelmus
Journal:  Trans Am Ophthalmol Soc       Date:  2000

Review 5.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

6.  Macrophage dependence of polyriboinosinic acid-polyribocytidylic acid-induced resistance to herpes simplex virus infection in mice.

Authors:  D Martinez; R J Lynch; J B Meeker; A K Field
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

7.  The effect of poly I:C and IUDR on the inhibition of HSV in rabbit eyes.

Authors:  O Smetana; E Eylan; N Kariv
Journal:  Med Microbiol Immunol       Date:  1982       Impact factor: 3.402

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.